1. Home >
  2. M&A >
  3. Divestiture >
  4. United Kingdom >
  5. Macrophage Pharma Acquires Chroma Therapeutics - Esterase Sensitive Motif

M&A Deal Summary

Macrophage Pharma Acquires Chroma Therapeutics - Esterase Sensitive Motif

On January 9, 2017, Macrophage Pharma acquired life science company Chroma Therapeutics - Esterase Sensitive Motif from Chroma Therapeutics

Acquisition Highlights
  • This is Macrophage Pharma’s 1st transaction in the Life Science sector.
  • This is Macrophage Pharma’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2017-01-09
Target Chroma Therapeutics - Esterase Sensitive Motif
Sector Life Science
Buyer(s) Macrophage Pharma
Sellers(s) Chroma Therapeutics
Deal Type Divestiture

Target

Chroma Therapeutics - Esterase Sensitive Motif

Abingdon, United Kingdom
Chroma Therapeutics Ltd. - Esterase Sensitive Motif is a platform delivers small molecule drugs to tumour associated macrophages in a highly selective manner, thus activating the body's natural immune system to fight cancer. The platform has the ability to provide next-generation immunotherapies for a number of different cancers.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Macrophage Pharma

Berkhamsted, United Kingdom
Category Company
Sector Life Science
DESCRIPTION

Macrophage Pharma Ltd. is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: United Kingdom M&A 1 of 1
Year: 2017 M&A 1 of 1

Seller(S) 1

SELLER

Chroma Therapeutics

Abingdon, United Kingdom
Category Company
Founded 2000
Sector Life Science
DESCRIPTION

Chroma Therapeutics is a new cancer drug discovery company with first-mover advantage in the field of chromatin biology. Chroma Therapeutics was founded in 2000 and is based in Abingdon, United Kingdom.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: United Kingdom M&A 1 of 1
Year: 2017 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal